FGP
SYRE icon

Freestone Grove Partners’s Spyre Therapeutics SYRE Stock Holding History

Freestone Grove Partners’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.02M Buy
+22,777
New +$1.66M 0.01% 421

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Freestone Grove Partners's SYRE Position: Q2 2026 in Review

Freestone Grove Partners opened a new position in Spyre Therapeutics (SYRE) in Q2 2026: 22,777 shares worth $2.02M. The stake represents 0.01% of the portfolio and ranks #421 among its holdings.

265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Freestone Grove Partners held 22,777 shares of Spyre Therapeutics worth $2.02M as of Q2 2026.
  • Spyre Therapeutics was a new Freestone Grove Partners position in Q2 2026.
  • Spyre Therapeutics made up 0.01% of Freestone Grove Partners's portfolio in Q2 2026, its #421 holding.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.